Intelligence · Clinical Pipeline
Boehringer Ingelheim Pipeline
All ClinicalTrials.gov programs at Boehringer Ingelheim — phase, modality, and trial IDs.
- Programs
- 62
Quick answer
Boehringer Ingelheim has 62 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
fixed dose combination of telmisartan+amlodipine
Boehringer Ingelheim
Hypertension
1 trial -
linagliptine 5 mg
Boehringer Ingelheim
Diabetes Mellitus, Type 2
1 trial -
nintedanib, Nintedanib, nintedanib
Boehringer Ingelheim
Childhood Interstitial Lung Disease
1 trial -
obrixtamig
Boehringer Ingelheim
Small Cell Lung Cancer (SCLC)
1 trial -
placebo
Boehringer Ingelheim
Pulmonary Fibrosis
1 trial -
placebo plus docetaxel
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
1 trial -
survodutide
Boehringer Ingelheim
Obesity
1 trial -
telmisartan/amlodipine 40/5 mg fixed combination
Boehringer Ingelheim
Hypertension
1 trial -
tiotropium
Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
1 trial -
tiotropium + olodaterol
Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
1 trial -
tiotropium 5mcg/day
Boehringer Ingelheim
Asthma
1 trial -
tiotropium high dose
Boehringer Ingelheim
Asthma
1 trial -
warfarin
Boehringer Ingelheim
Atrial Fibrillation
1 trial -
zongertinib
Boehringer Ingelheim
Lung Cancer, Non-squamous, Non-small Cell
1 trial
Frequently asked questions
How many pipeline programs does Boehringer Ingelheim have?
62 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs